ARS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share information)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Product revenue, net | $7,255 | $— |
| Revenue under collaboration agreements | 81,529 | 30 |
| Revenue under supply agreements | 365 | — |
| Total revenue | 89,149 | 30 |
| Operating expenses: | ||
| Cost of goods sold (including related party amounts of $241 and $0, respectively) | 977 | — |
| Research and development (including related party amounts of $2,066 and $1,796, respectively) | 19,580 | 20,266 |
| Selling, general and administrative (including related party amounts of $465 and $940, respectively) | 71,675 | 47,284 |
| Total operating expenses | 92,232 | 67,550 |
| Loss from operations | (3,083) | (67,520) |
| Other income, net | 11,369 | 13,155 |
| Income (loss) before income taxes | 8,286 | (54,365) |
| Income tax provision | 288 | — |
| Net income (loss) | $7,998 | $(54,365) |
| Change in unrealized gains and losses on available-for-sale securities | 171 | (358) |
| Comprehensive income (loss) | $8,169 | $(54,723) |
| Net income (loss) per share: | ||
| Basic | $0.08 | $(0.57) |
| Diluted | $0.08 | $(0.57) |
| Weighted-average shares outstanding used in computing net income (loss) per share: | ||
| Basic | 96,936,661 | 95,215,322 |
| Diluted | 102,390,828 | 95,215,322 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.